Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection?

Harris, Amanda E.; Styczyński, Jan; Bodge, Megan; Mohty, Mohamad; Savani, Bipin N.; Ljungman, Per

doi:10.1038/bmt.2015.49

Cited by 43 publications

(35 citation statements)

References 38 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, despite an extensive effort, studies are still inconclusive and have not shown any beneficial effect in preventing infections. 45 In addition, there are ethical issues related to donor immunization. As a result, the 2013 Infectious Diseases Society of America guidelines recommend against immunizing the donor solely for the benefit of the recipient.…”

Section: Donor Vaccinationmentioning

confidence: 99%

Immune reconstitution following stem cell transplantation

2015

View full text Add to dashboard Cite

Section: Donor Vaccinationmentioning

confidence: 99%

Immune reconstitution following stem cell transplantation

2015

View full text Add to dashboard Cite

“…98 No CMV vaccine has regulatory approval for prevention of CMV infection in normal individuals but a number of vaccine candidates are under investigation. A recombinant glycoprotein B vaccine was trialled in seronegative and seropositive solid organ transplant recipients prior to transplant with significant improvement shown in antibody titres in both serogroups, along with a reduction in duration of viraemia and antiviral treatment required in DC/R¡ patients who reactivated post transplant.…”

Section: Vaccinationmentioning

confidence: 99%

CMV-specific immune reconstitution following allogeneic stem cell transplantation

et al. 2016

View full text Add to dashboard Cite

Cytomegalovirus (CMV) remains a major contributor to morbidity and mortality following allogeneic haemopoietic stem cell transplant (HSCT) despite widespread use of viraemia monitoring and preemptive antiviral therapy. Uncontrolled viral replication occurs primarily in the first 100 d post transplant but this high risk period can extend to many months if immune recovery is delayed. The re-establishment of a functional population of cellular effectors is essential for control of virus replication and depends on recipient and donor serostatus, the stem cell source, degree of HLA matching and post-transplant factors such as CMV antigen exposure, presence of GVHD and ongoing use of immune suppression. A number of immune monitoring assays exist but have not yet become widely accessible for routine clinical use. Vaccination, adoptive transfer of CMV specific T cells and a number of graft engineering processes are being evaluated to enhance of CMV specific immune recovery post HSCT.

show abstract

“…However, if de novo or 'booster' vaccination of the donor is not possible, long-term antiviral prophylaxis and vaccination of the recipient would be an alternative. 4 Extending current literature, 3 we were able to show that after transplantation cellular HBV immunity was detectable in previously HBsAg-positive stem cell recipients. This is important because HBV-specific T cells are a prerequisite to control HBV infection.…”

mentioning

confidence: 62%

“…1,2 To overcome HBV reactivation, active immunization of donors and early post-transplant vaccination of recipients has been suggested. 3,4 This recommendation is based on the fact that adoptive immune transfer from HBVvaccinated donors was detected after hematopoietic stem cell transplantation. 3,[5][6][7][8][9] However, protection from reactivation depended on vigorous HBV immunity in the donor.…”

mentioning

confidence: 99%